Key MessageWe demonstrate the role for matched germline/tumour whole-genome sequencing and somatic mutational signatures to give insight into the aetiology of high-risk familial breast cancer. We illustrate how the approach can improve the diagnosis and management of individuals and their families by clarifying germline pathogenicity and enhancing the selection of platinum-based or PARP inhibitor therapy.

Introduction
============

Approximately 15%--20% of breast cancers (BCs) are associated with a strong family history of the disease. Pathogenic variants in *BRCA1, BRCA2* or other moderate to highly penetrant susceptibility genes (e.g. *TP53*, *ATM*, *CHEK2*, *PALB2* and *PTEN*) account for \<50% of familial BC and thus for the majority of families the underlying genetic contribution to their cancer risk remains unknown. Approximately 10% of individuals may benefit from the identification of germline pathogenic variants using multigene panel sequencing; however, little insight is gained for a large number of individuals and there is an increasing identification of variants of uncertain significance (VUS) \[[@mdz132-B1]\]. Germline testing is also impacting therapy, since carriers of germline pathogenic *BRCA1/2* variants derive enhanced benefit from platinum-based chemotherapy or poly(ADP-ribose) polymerase inhibitors (PARPi) \[[@mdz132-B2]\].

WGS detects a broad repertoire of somatic and/or germline alterations in an unbiased manner. The frequency and distribution of somatic mutations serve as an imprint, or signature, of mutational processes or exposures that contribute to tumour development \[[@mdz132-B8]\]. Some somatic mutational signatures are strongly linked to pathogenic germline variants in risk genes that play functional roles in DNA repair; for instance, homologous recombination (HR; *BRCA1, BRCA2*), mismatch repair (*MLH1, MSH2, MSH6*) or base excision repair (BER; *MUTYH*) \[[@mdz132-B7], [@mdz132-B11]\]. In BC, 12 substitution and 6 structural rearrangement signatures were identified \[[@mdz132-B9]\]. The combination of these signatures was used to develop HRDetect, a robust predictor of BRCA-deficiency and hence PARPi benefit \[[@mdz132-B7]\].

Methods
=======

We analysed 78 tumours from high-risk familial BC patients to investigate how WGS could impact the management of both risk and therapy for individuals and their families. Cases were carriers of a *BRCA1* pathogenic germline variant (*n* = 26), a *BRCA2* pathogenic germline variant (*n* = 22) or neither (non-*BRCA1/2*, *n* = 30) ([supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). In order to characterise the somatic landscape of these cases, matched germline/tumour DNA underwent WGS using Illumina X-Ten sequencing to an average fold depth of 34× and 68×, respectively. WGS data were analysed to characterise somatic mutations \[single nucleotide variants (SNVs), insertions-deletions, structural variants, copy number\], mutational signatures and measures of HR-deficiency (HRDetect, HRD Index) ([supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). This approach highlighted important mechanisms of genomic instability that underly familial BC.

Please refer to [supplementary Material](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online for details.

Results
=======

Somatic landscape of familial BC
--------------------------------

The somatic mutational landscape differed between tumours from *BRCA1, BRCA2* and non*-BRCA1/2* carriers (Figure [1](#mdz132-F1){ref-type="fig"}; [supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online**)**. Seventy-nine out of the 93 previously identified BC driver genes \[[@mdz132-B9]\] were mutated in at least one tumour; including a high frequency of mutations in *TP53* (88%) in *BRCA1*-tumours and *GATA3/PIK3CA* (50%) in non-*BRCA1/2*-tumours ([supplementary Figure S2](#sup1){ref-type="supplementary-material"}, [Tables S3 and S4](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). *BRCA1-* and *BRCA2*-tumours harboured more small deletions and SNVs compared with non-*BRCA1/2* tumours; and *BRCA1*-tumours exhibited a higher number of structural rearrangements including duplications and translocations compared with *BRCA2* and non-*BRCA1/2* tumours (both *P* ≤ 0.001, Mann--Whitney *U* test).

![Somatic mutational landscape of 78 familial breast cancers grouped by BRCA status determined by original clinical diagnosis. (A) Clinical information for each sample includes: germline pathogenic variant status from clinical testing of *BRCA1* and *BRCA2* genes, gender, age at diagnosis, tumour morphological type, histological grade and biomarker status for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). (B) The number of somatic indels per sample. (C) Number of somatic single nucleotide variants (SNVs). (D) Number and type of somatic structural rearrangements. IC NST, Invasive Carcinoma No Special Type; MDL, Mixed Ductal-Lobular Carcinoma; DCIS, Ductal Carcinoma In Situ; ILC, Invasive Lobular Carcinoma; Med. Ca., Medullary Carcinoma; Met. Ca., Metaplastic Carcinoma; Muc. Ca., Mucinous Carcinoma; \#, number; n/a, not available.](mdz132f1){#mdz132-F1}

Five substitution and five rearrangement signatures \[[@mdz132-B8], [@mdz132-B9]\] were identified (Figure [2](#mdz132-F2){ref-type="fig"}; [supplementary Figure S3](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). *BRCA1-*tumours had the highest proportion of substitution signature 3 and rearrangement signature 3; while *BRCA2-*tumours had the highest burden of substitution signature 8 and rearrangement signature 5 (both *P* ≤ 0.001, Mann--Whitney *U* test).

![Somatic mutational signatures in familial breast cancer. (A) Five substitution mutational signatures were identified and cosine similarity was used to compare the signatures to known signatures in COSMIC (Mutational Signatures v2 - March 2015; signatures were assigned based on highest similarity). (B) Five somatic rearrangement signatures were identified and cosine similarity was used to compare to rearrangement signatures previously reported in breast cancers \[[@mdz132-B9]\]. Rearrangements were grouped as clustered in the genome or not, then grouped by type: deletion (Del), duplication (Dup), inversion (Inv), or translocations (T); and then by size (as indicated on the *x*-axis). (C) The proportion of each substitution signature present per tumour (see colour coding in legend): Tumours from *BRCA1* carriers had a higher proportion of substitution signature 3 (orange); tumours from *BRCA2* carriers had a higher proportion substitution signature 8 (purple); tumours from non-*BRCA1/2* cases had heterogeneous patterns of signatures, but a high proportion of substitution signature 1 (previously associated with age; green). One tumour had a dominant signature 18 (*MUTYH*, blue) and one tumour had a prominent signature 13 (APOBEC, red). (D) The proportion of each rearrangement signature per tumour (see colour coding in legend): Tumours from *BRCA1* carriers had a higher proportion of rearrangement signature 3 (blue), tumours from *BRCA2* carriers had higher proportion of rearrangement signature 5 (light blue); tumours from non-*BRCA1/2* cases had heterogeneous patterns of rearrangement signatures, but the highest proportion of rearrangement signatures 4 (green) and 2 (purple).](mdz132f2){#mdz132-F2}

The mutation profile of non-*BRCA1/2*-tumours was diverse, suggesting a likely heterogeneous aetiology. Tumours had: (i) quiet genomes with few somatic mutations, (ii) a high SNV burden associated with APOBEC substitution signature \[[@mdz132-B8]\], (iii) a high burden of rearrangement signature 4 (clustered rearrangements), or (iv) mutational signatures suggesting *BRCA1/2*-deficiency (Figures [1](#mdz132-F1){ref-type="fig"} and [2](#mdz132-F2){ref-type="fig"}; [supplementary Figures S1--S3](#sup1){ref-type="supplementary-material"} and [Table S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

Somatic mutational signatures to stratify tumours
-------------------------------------------------

Unsupervised hierarchical clustering based on the contribution of multiple mutational signatures in each tumour stratified the cohort into three groups that broadly captured germline status, hence these groups were termed '*BRCA1*-like', '*BRCA2*-like' or 'non-*BRCA1/2*-like' (Figure [3](#mdz132-F3){ref-type="fig"}). Ten tumours (13%) clustered away from their 'original BRCA status', including two *BRCA1-*, two *BRCA2-* and six non-*BRCA1/2*-tumours. All tumours stratified as 'non-*BRCA1/2*-like' were BRCA-proficient (HRDetect scores \<0.7), while all '*BRCA1*-like' and '*BRCA2*-like' tumours were BRCA-deficient (Figure [3](#mdz132-F3){ref-type="fig"}; [supplementary Figure S4](#sup1){ref-type="supplementary-material"} and [Table S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). We show that the combination of multiple mutational signatures or HRDetect \[[@mdz132-B7]\] enabled better classification of the HR status in tumours than when using individual mutational signatures alone (Figure [3](#mdz132-F3){ref-type="fig"}; [supplementary Figure S4](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

![Stratification of tumours using unsupervised hierarchical clustering of the somatic mutational signatures. (A) Hierarchical clustering of the somatic genomic characteristics was based on the percentage contribution of each mutational signature per tumour (see colour coding at bottom), the ratio of insertion to deletions, and the HRD index \[[@mdz132-B3], [@mdz132-B4]\] using the Euclidean method for dissimilarity matrix and Ward.D2 for hierarchical clustering. Tumours were stratified into three groups based mainly on BRCA status (germline carriers of *BRCA1* or *BRCA2* or non-BRCA1/2) and so the three groups were termed '*BRCA1*-like', '*BRCA2*-like', or 'non-*BRCA1/2*-like'. (B) Number of mutations in each tumour, including insertion and deletions, SNVs and structural rearrangements coloured by the number of mutations associated with the different mutational signatures. (C) Panel shows HRDetect scores \[[@mdz132-B7]\] (the cut-off for HR-deficiency in the original study \>0.7; all *BRCA1*- and *BRCA2*-like tumours had a score \>0.99) and the presence of pathogenic germline variants and/or somatic alterations observed in *BRCA1* or *BRCA2*. (D) Clinical information and tumour features according to Figure [1](#mdz132-F1){ref-type="fig"}, together with tumour codes for cases discussed in text. (E) Examples of circos plots from each subgroup showing characteristic patterns of structural rearrangements. From the left: FBC050727 (non-*BRCA1/2*), FBC070474 (clustered rearrangements), FBC061542 (*BRCA2* biallelic inactivation), FBC020031 (*PALB2* biallelic inactivation), FBC060031 (*BRCA1* biallelic inactivation), FBC060116 (*BRCA1* promoter methylation/LOH). VUS, variant of unknown clinical significance; LOH, loss of heterozygosity; n/a, not available.](mdz132f3){#mdz132-F3}

WGS characteristics of tumours with '*BRCA1*-like' mutational signatures
------------------------------------------------------------------------

Twenty-nine tumours showed '*BRCA1*-like' mutational signatures; all had biallelic inactivation of *BRCA1* and were BRCA-deficient according to HRDetect. Most tumours were grade-3 and triple-negative, but included two histological grade-2, four ER/PR-positive and three HER2-positive tumours (Figure [3](#mdz132-F3){ref-type="fig"}).

Previously undetected carriers of dual germline pathogenic variants were discovered by WGS-derived mutational signatures. Case FBC090235 carried a *BRCA2* germline pathogenic variant (c.574_575delAT; p.Met192ValfsX13) identified by germline testing. WGS revealed not only mono-allelic loss of *BRCA2* but also a *BRCA1* germline structural rearrangement (chr17: g.41230286_41236428dup) coupled with somatic loss of the wild-type allele (Figure [3](#mdz132-F3){ref-type="fig"}; [supplementary Figure S5](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Case FBC070205 carried a *BRCA1* germline pathogenic variant (c.5244_5245delAA; p.Lys1748fs) and somatic loss of the wild-type allele, and the tumour showed a high contribution of the somatic rearrangement signature 3. However, substitution signatures were dominated by C\>A transversions in NpCpA or NpCpT contexts (Figures [2](#mdz132-F2){ref-type="fig"} and [3](#mdz132-F3){ref-type="fig"}) previously associated with inactivation of the BER gene *MUTYH* \[[@mdz132-B11]\]. We subsequently identified a *MUTYH* germline pathogenic variant (c.1556G\>A; p.Arg519Gln) and somatic loss of the wild-type allele ([supplementary Figure S6](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). The biallelic inactivation of both genes, together with evidence of their mutational signatures suggest that both genes contributed to tumourigenesis.

Four non-*BRCA1/2*-tumours harboured mutational signatures suggestive of *BRCA1* loss-of-function (cases FBC020021, FBC040626, FBC060116, FBC050467) (Figure [3](#mdz132-F3){ref-type="fig"}). Each tumour had somatic LOH of *BRCA1* and three exhibited somatic *BRCA1* promoter methylation (case FBC050467 had insufficient tumour DNA for methylation assessment). *BRCA1* promoter methylation was tested in the blood of all four cases and other family members, but all were found to be unmethylated, suggesting that these tumours are likely driven by somatic biallelic inactivation of *BRCA1* ([supplementary Figure S7](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). We found no evidence of biallelic inactivation of 52 additional genes involved in the HR pathway \[[@mdz132-B12]\] that could account for the HR defective signatures ([supplementary Tables S3--S6](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

WGS characteristics of tumours with '*BRCA2*-like' mutational signatures
------------------------------------------------------------------------

Twenty-four tumours contained '*BRCA2*-like' signatures and all were *BRCA1/2*-deficient according to HRDetect. This group included 20 of the 22 *BRCA2-*tumours, each with biallelic inactivation of *BRCA2*; 19 ER/PR-positive tumours, 9 grade-2 tumours, and 2 invasive lobular carcinomas (Figure [3](#mdz132-F3){ref-type="fig"}).

WGS of non-*BRCA1/2* case FBC020031 confirmed the previously identified *PALB2* nonsense variant (rs180177132; c.3113G\>A p.Trp1038\*) and detected somatic loss of the wild-type allele. The tumour was '*BRCA2*-like' with a high burden of substitution signature 3 and rearrangement signature 5 supporting previous studies linking loss of PALB2 function with BRCA-deficient signatures \[[@mdz132-B7], [@mdz132-B10], [@mdz132-B13]\].

Non-*BRCA1/2* case FBC060681 harboured a *BRCA2* VUS (c.7828G\>A p.Val2610Met). The tumour presented somatic loss of the wild-type allele, as well as '*BRCA2*-like' mutational signatures. The variant was not reported in gnomAD or in the 560 BC genomes cohort \[[@mdz132-B9]\] and is described by ClinVar (Variation ID: 135816) as 'Class 3 Uncertain significance' ([supplementary Table S5](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). The variant is in a highly conserved amino acid and is predicted to create a *de novo* donor splice-site in exon 17, although no experimental evidence supported this \[[@mdz132-B14]\]. Protein modelling of the variant predicted a damaging effect on protein structure and function ([supplementary Figure S8](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). No evidence of biallelic inactivation in 52 HR-related genes \[[@mdz132-B12]\] were identified in this case ([supplementary Tables S3--S6](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

WGS characteristics of tumours with 'non-*BRCA1/2*-like' mutational signatures
------------------------------------------------------------------------------

Twenty-five tumours were classified as 'non-*BRCA1/2*-like' and included 24 tumours from non-*BRCA1/2* cases and a *BRCA2*-tumour (FBC016006, NM_000059.3, c.1310_1313delAAGA) that lacked somatic inactivation of the *BRCA2* wild-type allele ([supplementary Figure S9](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Twenty-two tumours were ER/PR-positive; six were HER2-positive; and all were considered BRCA-proficient (Figure [3](#mdz132-F3){ref-type="fig"}). Case FBC070169 had a strong APOBEC substitution signature accounting for 94% of the somatic mutations, yet there was no evidence of the *APOBEC3A* or *APOBEC3B* germline variants previously associated with this signature \[[@mdz132-B15], [@mdz132-B16]\].

Unsupervised hierarchical clustering stratified the 'non-*BRCA1/2*-like' tumours into two groups based on the contributions of rearrangement signatures 1, 2 and 4 (Figures [3](#mdz132-F3){ref-type="fig"} and [4](#mdz132-F4){ref-type="fig"}; [supplementary Figure S10](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Twelve tumours had either relatively quiet genomes dominated by rearrangement signature 2 (*n* = 9; with recurrent gain of 1q and/or loss of 16q) or rearrangement signature 1 (*n* = 3). The remaining thirteen tumours were younger at diagnosis (median age 44 versus 62 years) and displayed a high contribution of rearrangement signature 4, involving complex rearrangements clustered to one or a few chromosomes. These clustered events coincided with amplifications of known BC oncogenes (e.g. *ZNF217*, *ERBB2*, *CCND1*, *MYC*) \[[@mdz132-B9]\], and in 8/13 tumours, the patterns of rearrangements suggested evidence for Breakage--Fusion--Bridge (BFB) cycles; two additional tumours had events resembling chromothripsis and BFB (Figure [4](#mdz132-F4){ref-type="fig"}). We observed that 'non-*BRCA1/2*-like' tumours had shorter telomeres than *BRCA*-deficient tumours ([supplementary Figure S11](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online) raising the possibility that dicentric chromosome formation due to telomeric erosion could lead to BFB and/or chromothripsis \[[@mdz132-B17], [@mdz132-B18]\]. We were unable to identify germline or somatic variants in candidate genes associated with chromosomal segregation or telomere maintenance that could potentially lead to this pattern of rearrangements. In four cases, however, we identified rare germline variants in *TP53* (NM_000546.5: c.1009C\>T), *ATM* (NM_000051.3: c.4909+1G\>A) and *CHEK2* (NM_007194.3: c.349A\>G; NM_007194.3: c.1100delC), together with somatic loss of the wild-type allele, implying functional loss of the relevant protein (Figure [4](#mdz132-F4){ref-type="fig"}).

![Whole-genome DNA copy number profile of non-*BRCA1/2*-like tumours. (A) Chromosome arm level copy number data \[gains (red) and losses (blue)\] across the genome in non-*BRCA1/2*-like tumours stratified according to rearrangement signatures 1, 2, and 4. Tumours are plotted in the same order as Figure [3](#mdz132-F3){ref-type="fig"}. Tumours are identified which: harbour germline pathogenic variants in risk genes *ATM, TP53* or *CHEK2*; show evidence of Break--Fusion--Bridge and/or chromothripsis; and harbour amplification of various oncogenes. (B) The distribution of histological grade was not significantly different (χ^2^). (C) Non-*BRCA1/2*-like tumours with a high proportion of rearrangement signature 4 (clustered rearrangements) were diagnosed at a significantly younger age to non-*BRCA1/2* tumours with other genome characteristics (Mann -Whitney U test, two-tailed). (D) Circos plots are shown for the cases with germline variants in *ATM*, *TP53* and *CHEK2*.](mdz132f4){#mdz132-F4}

Discussion
==========

This study represents the largest cohort of familial BC cases examined by WGS, and the first report from high-risk, non-*BRCA1/2* families. The findings demonstrate the impact that combined germline and somatic WGS can offer as a companion diagnostic in clarifying cancer risk in individuals and in aiding decisions regarding treatment. We confirm the importance of biallelic inactivation of germline risk genes to drive the accumulation of specific patterns of somatic mutational signatures. Loss of function of *BRCA1, BRCA2* and *PALB2* yield a high mutation burden and specific signatures inferring defective HR \[[@mdz132-B7], [@mdz132-B9], [@mdz132-B10], [@mdz132-B13]\]. Despite the role of *TP53, ATM* and *CHEK2* in DNA-damage signalling and double-strand breaks detection, these tumours do not show evidence of BRCA-deficient signatures, as previously described \[[@mdz132-B9], [@mdz132-B13], [@mdz132-B19]\], but instead they harbour highly complex clustered chromosomal rearrangements.

WGS-derived signatures identified two individuals as carriers of dual germline pathogenic variants (*BRCA1/BRCA2* and *BRCA1/MUTYH)*, which were previously unreported. Mutation signatures indicated that biallelic inactivation of *BRCA1* rather than *BRCA2* was driving tumorigenesis in the *BRCA1/BRCA2* case. Clinical *BRCA1* and *BRCA2* testing (in 2004) identified a pathogenic *BRCA2* germline variant (c.574_575delAT; Met192ValfsX13), thus further testing was not pursued. During this study, a family member diagnosed with BC was found not to carry this variant, and more extensive testing revealed the *BRCA1* germline rearrangement. Segregation of disease in the *BRCA1/BRCA2* family was incomplete until the *BRCA1* rearrangement was considered. Co-occurring germline pathogenic variants in *BRCA1* and *BRCA2* are rare (0.3%, 93/32,295 cases) and carriers are more likely to be diagnosed with BC than *BRCA1* or *BRCA2* only carriers \[[@mdz132-B20]\]. Little is known about the incidence and risk profile for *BRCA1*/*MUTYH* carriers, and biospecimens from other family members were unavailable, so it was unclear how the variants segregate with disease. However, it is clear that biallelic inactivation of both genes contributed to tumorigenesis. These cases exemplify the importance of thorough germline testing and the power of WGS as a single test to (i) screen entire genes for different types of variants (SNV and rearrangements); and (ii) derive somatic mutational signatures for both variant discovery and delineating the aetiology of disease.

Several lines of evidence support that the *BRCA2* VUS (c.7828G\>A p.Val2610Met) contributed to tumorigenesis: (i) somatic biallelic inactivation of *BRCA2* (VUS and LOH); (ii) the tumour was '*BRCA2*-like' according to the pattern of mutation signatures and was BRCA-deficient according to HRDetect; (iii) no variants were identified in other HR pathway genes that could explain this BRCA-deficiency; and (iv) protein modelling predicted a negative impact on protein function. This rare variant has only been described once in the literature \[[@mdz132-B14]\], evaluating the same individual as reported here. Further investigation of the pathogenicity of this rare p.Val2610Met variant is warranted.

Most familial BC fall under the umbrella term of non-*BRCA1/2*, involving germline variants in other moderate- to highly penetrant genes, or where the underlying genetic cause is unknown. Non-*BRCA1/2* tumours exhibit considerable morphological \[[@mdz132-B21]\], molecular \[[@mdz132-B22]\] and genomic heterogeneity. WGS provided evidence regarding the drivers of tumorigenesis in many cases, including germline carriers of variants in *BRCA2* (VUS), *PALB2, CHEK2, ATM* and *TP53; BRCA1* promoter methylation, APOBEC mutagenesis and oncogene amplification.

The subgroup of 'non-*BRCA1/2*-like' tumours harbouring complex patterns of clustered structural rearrangements was early onset cancers with an ER-positive and/or HER2-positive phenotype. The complex rearrangements were associated with amplification of various oncogenes and showed evidence of BFB and chromothripsis as a potential mechanism driving tumorigenesis \[[@mdz132-B18]\]. Four cases within this group harboured germline pathogenic variants in *ATM* \[[@mdz132-B23]\], *CHEK2* \[[@mdz132-B24]\] or *TP53* \[[@mdz132-B25]\], all with somatic LOH. Chromothripsis and BFB have been reported in numerous tumour types, and intriguingly, germline variants in *ATM* and *TP53* were associated with such complex structural rearrangements in acute lymphoblastic leukaemia \[[@mdz132-B26]\] and medulloblastoma \[[@mdz132-B27]\]. Whilst these patterns of rearrangements have been reported in BC \[[@mdz132-B28], [@mdz132-B29]\], they have not been associated with a germline predisposition. Interestingly, \>60% of BC in germline *TP53* carriers are *ERBB2*/*HER2* amplified \[[@mdz132-B30]\] and complex structural rearrangements are suggested to drive amplification in such cancers \[[@mdz132-B29]\].

Better predicting response to therapy is critical to advance oncology. Investigators have used various means to improve the utility of DNA-damaging chemotherapies and PARPi, for instance: the germline status of *BRCA1* or *BRCA2*; somatic LOH of these genes; a triple-negative tumour phenotype; or patterns of somatic mutations \[[@mdz132-B2]\]. We confirm the utility of WGS and HRDetect \[[@mdz132-B7]\] to enhance the stratification of tumours as being BRCA-proficient versus deficient compared with individual genomic parameters (e.g. HRD score and substitution signature 3). Using this approach, all *BRCA1*-tumours, 91% of *BRCA2*-tumours and the *PALB2* tumour had bialleic inactivation of said gene and strong evidence of HR-deficiency. These cases would be predicted to be good candidates for platinum-based chemotherapy or PARPi, and included 12 tumours that would not otherwise fall into this recommendation of treatment (i.e. histological grade-2, ER/PR-positive \[[@mdz132-B31]\], or invasive lobular carcinoma). In contrast to a recent report, only two tumours (2/22, 9% versus 46% \[[@mdz132-B5]\]) from *BRCA2* carriers did not exhibit biallelic inactivation of the gene; one tumour was BRCA-deficient due to the biallelic inactivation of *BRCA1*, whereas the other was BRCA-proficient, and hence this latter patient would be unlikely to benefit from such therapies.

In summary, matched germline/tumour WGS can improve the identification of the underlying genetic cause of disease over *BRCA1* and *BRCA2* germline screening alone and that this will likely improve the clinical management of individuals and potentially their families. Furthermore, WGS yields the most robust assessment of BRCA-deficiency and can also identify oncogenic drivers in BRCA-proficient tumours, which collectively may enhance the selection of targeted therapies for patients.
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